La Jolla Pharma (LJPC) 22.95 $LJPC
Earnings Report Update: Free Research on Fate Therapeutics, La Jolla,FONAR, TASER, and Allied Motion
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
FATE: 5.91 (-0.24), FONR: 12.05 (+0.33), LJPC: 22.95 (-1.39), AMOT: 41.04 (+0.49), TASR: 29.67 (-0.01)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:46AM CDT
La Jolla Pharmaceutical (LJPC) was a big mover last session, with shares rising over 14% on the day.
LJPC: 22.95 (-1.39), ARQL: 2.12 (unch)
La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board
Business Wire - Wed Apr 22, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the addition of four new members to its advisory board for the development of LJPC-401, La Jolla's novel formulation of hepcidin. The advisory board is composed of internationally renowned clinicians, highly respected academics and key opinion leaders in the fields of gastroenterology, hematology and oncology. The new members of the advisory board are Paul Adams, M.D., Victor Gordeuk, M.D., Ashutosh Lal, M.D., and Gordon McLaren, M.D.
LJPC: 22.95 (-1.39)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.01 (-0.17), FATE: 5.91 (-0.24), HAS: 71.61 (-0.10), ADXS: 23.34 (-0.27), AMSC: 6.88 (-3.12), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), RMBS: 13.99 (-0.31), TGLS: 11.72 (-0.08), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 2.09 (+0.13), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), CEA: 40.74 (-2.76), NVGN: 6.54 (-0.01), NHLD: 3.78 (-0.18), VLTC: 11.54 (+0.50), GEVO: 2.72 (-0.10), BIOD: 1.14 (-0.13), PRTO: 12.30 (+0.01), TTS: 14.01 (-0.17), ENZN: 1.72 (+0.18), AST: 14.77 (+0.66), VGGL: 2.55 (-0.10), GLF: 13.58 (-0.05), NVTA: 13.23 (+0.41), FTK: 14.06 (-0.43), PGN: 1.69 (unch), UCTT: 6.26 (+0.60), SANM: 20.81 (-0.03)
5 Stocks Ready for Breakouts
at The Street - Fri Apr 17, 8:09AM CDT
These stocks look poised to break out and trade higher from current levels.
ANY: 4.08 (-0.19), LJPC: 22.95 (-1.39), PHMD: 2.05 (+0.09), TRAK: 39.43 (-0.11), AAPL: 130.28 (+0.61)
New finance chief at La Jolla Pharma
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:04AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer
Business Wire - Mon Apr 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Dennis Mulroy will join the Company as Chief Financial Officer, effective today.
LJPC: 22.95 (-1.39)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
La Jolla Pharmaceuticals: A Busy 2015 Ahead
Robert K. Stuart - at Seeking Alpha - Tue Mar 24, 11:53AM CDT
LJPC: 22.95 (-1.39), ICPT: 283.20 (-2.22)
La Jolla Pharma initiates late stage LJPC-501 trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:50AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire - Tue Mar 24, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, a Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In February 2015, La Jolla reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), in which it was agreed that the primary efficacy endpoint for the trial would be increase in blood pressure. CRH is an acute, life-threatening condition in which blood pressure drops to dangerously low levels in patients who respond poorly to current treatments.
LJPC: 22.95 (-1.39)
La Jolla Pharma starts Phase 2 kidney disease study
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:57AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease
Business Wire - Wed Mar 18, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced chronic kidney disease (CKD) caused by diabetes. CKD is a condition characterized by a gradual loss of kidney function over time that may eventually lead to kidney failure, requiring dialysis or a kidney transplant to maintain life.
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical posts 4Q loss
Automated Insights - Mon Mar 16, 5:58PM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Monday reported a loss of $6.8 million in its fourth quarter.
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical misses by $0.08
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 4:16PM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights
Business Wire - Mon Mar 16, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 22.95 (-1.39)
Earnings Report Update: Free Research on Fate Therapeutics, La Jolla,FONAR, TASER, and Allied Motion
PR Newswire - Thu Apr 23, 7:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
FATE: 5.91 (-0.24), FONR: 12.05 (+0.33), LJPC: 22.95 (-1.39), AMOT: 41.04 (+0.49), TASR: 29.67 (-0.01)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Up 14.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 8:46AM CDT
La Jolla Pharmaceutical (LJPC) was a big mover last session, with shares rising over 14% on the day.
LJPC: 22.95 (-1.39), ARQL: 2.12 (unch)
La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board
Business Wire - Wed Apr 22, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the addition of four new members to its advisory board for the development of LJPC-401, La Jolla's novel formulation of hepcidin. The advisory board is composed of internationally renowned clinicians, highly respected academics and key opinion leaders in the fields of gastroenterology, hematology and oncology. The new members of the advisory board are Paul Adams, M.D., Victor Gordeuk, M.D., Ashutosh Lal, M.D., and Gordon McLaren, M.D.
LJPC: 22.95 (-1.39)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 21, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
TTS: 14.01 (-0.17), FATE: 5.91 (-0.24), HAS: 71.61 (-0.10), ADXS: 23.34 (-0.27), AMSC: 6.88 (-3.12), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), RMBS: 13.99 (-0.31), TGLS: 11.72 (-0.08), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 11:47AM CDT
RNO: 2.09 (+0.13), ECHO: 32.68 (-1.14), LJPC: 22.95 (-1.39), CEA: 40.74 (-2.76), NVGN: 6.54 (-0.01), NHLD: 3.78 (-0.18), VLTC: 11.54 (+0.50), GEVO: 2.72 (-0.10), BIOD: 1.14 (-0.13), PRTO: 12.30 (+0.01), TTS: 14.01 (-0.17), ENZN: 1.72 (+0.18), AST: 14.77 (+0.66), VGGL: 2.55 (-0.10), GLF: 13.58 (-0.05), NVTA: 13.23 (+0.41), FTK: 14.06 (-0.43), PGN: 1.69 (unch), UCTT: 6.26 (+0.60), SANM: 20.81 (-0.03)
5 Stocks Ready for Breakouts
at The Street - Fri Apr 17, 8:09AM CDT
These stocks look poised to break out and trade higher from current levels.
ANY: 4.08 (-0.19), LJPC: 22.95 (-1.39), PHMD: 2.05 (+0.09), TRAK: 39.43 (-0.11), AAPL: 130.28 (+0.61)
New finance chief at La Jolla Pharma
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:04AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer
Business Wire - Mon Apr 06, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Dennis Mulroy will join the Company as Chief Financial Officer, effective today.
LJPC: 22.95 (-1.39)
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups
James Sands - at Seeking Alpha - Tue Mar 31, 8:40PM CDT
PCYC: 256.59 (-0.51), FB: 81.53 (-0.88), LJPC: 22.95 (-1.39), SAFM: 76.06 (-0.23), ICE: 223.39 (-1.80), ILMN: 189.59 (-3.01), HP: 74.42 (-0.91), PCLN: 1,233.09 (+11.99), WWAV: 45.60 (-0.08), SQNM: 4.52 (-0.10), ACAD: 38.36 (-0.54), HALO: 16.86 (-0.08), GILD: 103.69 (-1.52), TRN: 28.70 (-4.66), QCOM: 68.24 (-0.10), FFIV: 123.18 (+0.78), MBLY: 47.62 (+0.01), UNP: 107.51 (-0.61), MA: 90.72 (-0.16), IPGP: 94.50 (-2.04)
La Jolla Pharmaceuticals: A Busy 2015 Ahead
Robert K. Stuart - at Seeking Alpha - Tue Mar 24, 11:53AM CDT
LJPC: 22.95 (-1.39), ICPT: 283.20 (-2.22)
La Jolla Pharma initiates late stage LJPC-501 trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:50AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Business Wire - Tue Mar 24, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial, a Phase 3 clinical trial of LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). In February 2015, La Jolla reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA), in which it was agreed that the primary efficacy endpoint for the trial would be increase in blood pressure. CRH is an acute, life-threatening condition in which blood pressure drops to dangerously low levels in patients who respond poorly to current treatments.
LJPC: 22.95 (-1.39)
La Jolla Pharma starts Phase 2 kidney disease study
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:57AM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease
Business Wire - Wed Mar 18, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced chronic kidney disease (CKD) caused by diabetes. CKD is a condition characterized by a gradual loss of kidney function over time that may eventually lead to kidney failure, requiring dialysis or a kidney transplant to maintain life.
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical posts 4Q loss
Automated Insights - Mon Mar 16, 5:58PM CDT
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Monday reported a loss of $6.8 million in its fourth quarter.
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical misses by $0.08
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 4:16PM CDT
LJPC: 22.95 (-1.39)
La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights
Business Wire - Mon Mar 16, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 22.95 (-1.39)
